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Lentiviruses have been extensively used as gene delivery vectors since the mid-1990s.
Usually derived from the human immunodeficiency virus genome, they mediate efficient
gene transfer to non-dividing cells, including neurons and glia in the adult mammalian
brain. In addition, integration of the recombinant lentiviral construct into the host genome
provides permanent expression, including the progeny of dividing neural precursors.
In this review, we describe targeted vectors with modified envelope glycoproteins and
expression of transgenes under the regulation of cell-selective and inducible promoters.
This technology has broad utility to address fundamental questions in neuroscience
and we outline how this has been used in rodents and primates. Combining viral
tract tracing with immunohistochemistry and confocal or electron microscopy, lentiviral
vectors provide a tool to selectively label and trace specific neuronal populations at gross
or ultrastructural levels. Additionally, new generation optogenetic technologies can be
readily utilized to analyze neuronal circuit and gene functions in the mature mammalian
brain. Examples of these applications, limitations of current systems and prospects for
future developments to enhance neuroscience knowledge will be reviewed. Finally, we
will discuss how these vectors may be translated from gene therapy trials into the clinical
setting.
Keywords: lentivirus, temporal and spatial specificity, neuron phenotype, optogenetics, confocal and electron
microscopy
Recombinant Lentiviruses in Neuroscience
Lentiviral biology has been extensively studied since the early 1980s following evidence that
human immunodeﬁciency virus (HIV) was the causative agent of AIDS. Harnessing aspects of this
knowledge, gene therapy researchers developed recombinant viral vectors based on HIV (Verma
and Somia, 1997; Naldini, 1998), feline, and equine equivalents. Lentivirus is a member of the
Retroviridae family of viruses, named because reverse transcription of viral RNA genomes to DNA
is required before integration into the host genome. Unlike other retroviral genra, such as gamma-
retroviruses that are also used in gene therapy, lentiviruses are able to infect both dividing and
non-dividing cells by virtue of the entry mechanism through the intact host nuclear envelope
Frontiers in Molecular Neuroscience | www.frontiersin.org 1 May 2015 | Volume 8 | Article 14
Parr-Brownlie et al. Lentivirus tools to investigate brain function
(Naldini, 1998; Vodicka, 2001). This characteristic makes it an
ideal viral vector for neuroscience, where the majority of cells in
the postnatal brain do not divide.
Lentiviral genomes are single-stranded RNA with gag, pol
and env genes encoding polyprotein components of the capsid,
the enzymes reverse transcriptase, protease and integrase, and
envelope glycoproteins, respectively. The viral genome is ﬂanked
by long terminal repeats (LTRs), required for genome replica-
tion and integration (Naldini, 1998). Lentiviruses have additional
accessory genes, but these are dispensable in recombinant
vectors. Instead, a recombinant lentiviral vector genome contains
LTRs ﬂanking a packaging signal, plus an exogenous promoter
used to express a transgene that enables identiﬁcation of subpop-
ulations of cells, overexpression or knockdown of genes or to
target cells with a drug- or light-inducible protein to analyze cell
function (Dull et al., 1998). The genome capacity is 8–10 kb for
maximal packaging eﬃciency and viral particles are packaged in
human cell lines (usually HEK293 derivatives) by co-transfection
of helper plasmids encoding gag, pol, and env (Dull et al., 1998). In
post-mitotic cells, lentiviral vectors integrate at random, whereas
integration preferentially occurs into active genes in mitoti-
cally active cells (Bartholomae et al., 2011). An alternative and
additional safety aspect for post-mitotic cell transduction is the
development of integrase deﬁcient lentiviral vectors (Liu et al.,
2014). Removal of the integrase from the packaging construct
prevents integration, resulting in episomal maintenance of the
transgene vector in post-mitotic cells. Recombinant lentiviral
vectors appear to oﬀer greater safety over gamma retroviral
vectors in which activation of oncogenes has been reported
(Hacein-Bey-Abina et al., 2003; Zhou et al., 2010). Although
lentiviral vectors have some limitations, mainly in respect to
limited spread within the brain parenchyma, this provides an
additional advantage in some cases. Permanent integration of
lentiviral delivered transgenes into mitotic or post-mitotic cells,
similar to episomal maintenance of integrase-deﬁcient lentivirus
or AAV in post-mitotic cells, should allow stable transgene
expression for the life of the organism or cell, preventing the
need for repeated vector administration (Linterman et al., 2011).
An important advantage of lentiviral vectors over other vector
systems, including adeno-associated virus (AAV), is that inﬂam-
matory, and immune responses associated with the vector itself
are limited (Abordo-Adesida et al., 2005; Annoni et al., 2007).
This review highlights how lentiviral vectors have been used in
neuroscience research. We focus on targeting gene expression to
selected neuronal phenotypes, both spatially and temporally, to
answer speciﬁc biological questions surrounding gene function
and the anatomy and physiology of neural circuits in the mature
brain.
Targeting Gene Expression to
Structures and Cells
The design of lentiviral vectors has increased in complexity over
the last 20 years. As lentiviral vectors have been used as a tool
to address more reﬁned neuroscience questions, expectations for
increased spatial and temporal accuracy of gene expression have
resulted, making it more challenging to design new lentiviral
vectors for cutting edge experiments.
Transgene expression can be restricted (i) to certain structures
or cell types for reﬁned spatial resolution, (ii) in a constitu-
tive or inducible manner for temporal resolution, and (iii) by
activation of the gene product by additional stimuli like light or
drugs (post-translational regulation). Belowwe outline how these
restrictions are routinely used to improve knowledge of brain
circuitry.
Spatial Restriction of Gene Expression
In its simplest form, spatial restriction of gene expression is
achieved by injecting low volumes and/or titres of the lentiviral
vector in the target brain region where its spread will be restricted
depending on its tropism and diﬀusion through the target tissue.
Lentiviral tropism is deﬁned by the glycoproteins on the surface
of the viral particles that determine which cell surface receptor the
virus binds to and thereby the cells or subcellular compartments
the virus can enter. Tropism can be modiﬁed by pseudotyp-
ing, which is the expression of glycoproteins originating from
a diﬀerent virus (Indraccolo et al., 1998; Cronin et al., 2005;
Trabalza et al., 2013). The most common pseudotyping method
uses the vesicular stomatitis virus glycoprotein (VSVg). VSVg
pseudotyped particles have wide tropism as they use low-density
lipoprotein receptors to enter cells (Finkelshtein et al., 2013),
which are almost ubiquitously expressed on cell membranes
(Willnow, 1999), including by both glia and neurons (Jakobsson
et al., 2003). By diﬀerential pseudotyping, speciﬁc populations
of neurons within a brain region can be targeted (Figure 1A).
An example of diﬀerential tropism is in the hippocampus, where
VSVg pseudotyped vectors mainly transduce cells in the subgran-
ular zone and dentate granule cell layer, while murine leukemia
virus glycoprotein (MuLV) pseudotyped vectors more speciﬁcally
transduce mature granule cells (Watson et al., 2002).
Unlike AAVs, which have a diameter of approximately 20 nm,
the larger particle size of lentiviruses (100 nm) limits spread
through the extracellular space (Cetin et al., 2006; Lerchner
et al., 2014; Figure 1), and methods to increase AAV spread,
like convection-enhanced delivery or mannitol, are therefore not
promising for lentiviral particles. The spread of one microliter of
VSVg pseudotyped vector in the brain is restricted to 1–2 mm
from the injection site (Desmaris et al., 2001; Linterman et al.,
2011), with no retrograde transport. By exchanging the VSVg for
a rabies glycoprotein (Rbg; Mazarakis et al., 2001), or a chimera
of these two (Kato et al., 2011a,b, 2014; Carpentier et al., 2012;
Schoderboeck et al., 2015) retrograde transport is enabled so
that after transduction of axonal terminals, viral contents (minus
envelope) are transported to the cell body (Figure 1).
Cell-Specific Gene Expression Using
Promoters
The promoter controlling gene expression in the lentiviral
construct provides a further level of restriction. In addition to
ubiquitous promoters, a range of brain cell-type speciﬁc promot-
ers are available and well characterized. A list of promoters that
are frequently used in neuroscience research is detailed inTable 1.
Ubiquitous promoters that cause expression of non-native
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FIGURE 1 | Lentiviral vector spread, transduction, and expression is
mediated by particle size, envelope properties and promoter usage.
(A) Lentiviral vectors pseudotyped with vesicular stomatitis virus glycoprotein
(VSVg) mediate local transduction with no retrograde or trans-synaptic viral
transport. (B) In contrast, lentiviral vectors pseudotyped with a rabies
glycoprotein (Rbg) transduce both the soma of local neurons and also afferents
to the area. (C) AAV, depending on serotype, mediates larger physical spread,
and can transduce either local neurons or afferent terminals. (A–C) Schematics
of relative virus particle size represented in upper panels indicate that lentiviral
vectors are approximately 5 × larger than AAVs. (D) Transgene expression can
be restricted to specific cell types using specific promoters. Using the glial
fibrillary acidic protein (GFAP) promoter driving mCherry and synapsin promoter
to drive GFP, lentiviral constructs differentially label astrocytes, and neurons,
respectively.
proteins in virtually all transduced cells include elongation
factor 1 alpha (EF1α), cytomegalovirus enhancer/promoter
element (CMV), β-actin, β-globin chimeric promoter (CAG), and
phosphoglycerate kinase promoter (PGK; for a comparison see
(Qin et al., 2010) and (Yaguchi et al., 2013). Promoters provid-
ing speciﬁc expression in all neurons include synapsin 1 (syn;
Hioki et al., 2007; Nathanson et al., 2009; van Hooijdonk et al.,
2009; Yaguchi et al., 2013) and neuron speciﬁc enolase (NSE;
TABLE 1 | Commonly used promoters in lentiviruses.
Common abbreviation Promoter origin Expressed in Comments
EF1α Mammalian elongation factor 1 alpha promoter Ubiquitous Endogenous mammalian promoter (Jakobsson et al.,
2003).
CMV Human cytomegalovirus immediate-early
enhancer/promoter
Ubiquitous Methylation-dependent silencing of transgene expression
(Brooks et al., 2004)
CAG CMV coupled with chicken β-actin promoter and
first exon and rabbit β-globin splice acceptor.
Ubiquitous Stable long term expression (Jakobsson et al. (2003),
Delzor et al. (2012)).
PGK Mammalian phosphoglycerate kinase 1
promoter
Ubiquitous Endogenous mammalian gene Delzor et al. (2012)
MND Myeloproliferative sarcoma virus enhancer,
Negative control region deleted, dl587rev
primer-binding site substituted
Ubiquitous Li et al. (2010), Linterman et al. (2011)
Syn Mammalian synapsin 1 promoter Neurons Dittgen et al. (2004)
GAD67 Mammalian glutamate decarboxylase 67 Inhibitory neurons Nathanson et al. (2009), Delzor et al. (2012)
CaMKIIα Mammalian calcium/calmodulin-dependent
protein kinase II alpha promoter
Excitatory glutamatergic
neurons
Postnatal expression – later in development then synapsin
(Dittgen et al., 2004; van Hooijdonk et al., 2009).
NSE Mammalian neuron-specific enolase promoter Neurons Relatively weak expression (Delzor et al., 2012)
MBP Mammalian myelin basic protein promoter Oligodendrocytes McIver et al. (2005, 2010)
GFAP Mammalian glial fibrilliary acidic protein promoter Astrocytes Higher expression in activated astrocytes (Chow et al.,
2008).
Nes Mammalian nestin promoter Neural progenitor cells Can also be expressed in activated astrocytes.
(Beech et al., 2004; Cheng et al., 2004; Sun et al., 2014).
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Delzor et al., 2012). Neuronal type speciﬁc promoters, that have
a size compatible with lentiviral vectors are still limited, but
include calcium/calmodulin-dependent protein kinase II alpha
(CaMKIIα; Dittgen et al., 2004; van Hooijdonk et al., 2009;
Seeger-Armbruster et al., 2015), which restricts expression to
excitatory glutamatergic neurons and glutamate decarboxylase
67 (GAD67; Delzor et al., 2012) that should restrict expression
to inhibitory GABAergic neurons. The parvalbumin promoter
targets a subset of GABAergic neurons (Sohal et al., 2009) and
ppHcrt targets hypocretin neurons (Zhang et al., 2010). However,
because LV-VSVg has strong tropism for excitatory neurons,
transgene expression from the GAD67 promoter has also been
found in excitatory neurons (Nathanson et al., 2009). The glial
ﬁbrillary acid protein (GFAP) promoter is most commonly used
to restrict gene expression to astrocytes (Jakobsson et al., 2003),
myelin basic protein (MBP) to target oligodendrocytes (McIver
et al., 2005), and the nestin (nes) promoter for neural progeni-
tor cells (Beech et al., 2004). The speciﬁcity of these promoters
is not absolute and can be impaired by viral preparation proper-
ties (titre) and promoter properties in certain subregions of the
brain. Promoters used in lentiviral vectors typically only comprise
minimal promoter sequences, while their endogenous counter-
parts are often signiﬁcantly longer and more complex including
enhancer and insulator elements. Using a minimal promoter
sequence simpliﬁes cloning and helps keep the vector size small,
but this also compromises the speciﬁcity as parts of the promoter
or enhancer and insulator elements will be missing. Integration of
vectors close to enhancer or repressor sequences can also impact
vector promoter ﬁdelity.
Tighter cell-type speciﬁcity can be achieved by combin-
ing lentiviruses with the cre-lox system in transgenic animals.
The system involves two components: cre recombinase and a
transgene ﬂanked by lox sites (“ﬂoxed”), the recognition sites
for cre recombinase. The bacterial cre protein uses the lox
sites for site-speciﬁc recombination in mammalian cells (Sauer
and Henderson, 1988). Both components can be supplied by
viral vectors or a transgenic animal used to express either
cre recombinase, or a ﬂoxed transgene; either of which can
be controlled by a cell-type speciﬁc promoter (Figure 2). The
lentiviral vector supplies the other component (cre or ﬂoxed
transgene), which might include a protein under posttrans-
lational regulation (See Posttranslational Control of Gene
Expression).
Conditional knockdown of gene expression is another
powerful method to analyze protein function in the adult brain.
microRNA (miRNA)-based short hairpin knockdown can be
combined with cell speciﬁc promoters (Nielsen et al., 2009),
or used in combination with cre-lox or drug-inducible cre-lox
systems for spatial and temporal control of gene knockdown
(Stern et al., 2008; Heitz et al., 2014). For example, Heitz
et al. (2014) use a lentiviral vector expressing a ﬂoxed GFP
miRNA to transduce mice expressing GFAP or CaMKII regulated
tamoxifen-inducible cre (creERT2).
Further restriction of gene expression can be achieved by
miRNA de-targeting. In this system, incorporating miR binding
sites into the 3′ UTR of transgene constructs within a viral vector
limits expression to those cells that do not express that miR.
FIGURE 2 | A potential use of Cre–lox and cell specific promoters to
target gene expression both spatially and temporally. (A) A lentiviral
vector (LV- synapsin-double-floxed mCherry) injected in the hippocampal
dentate gyrus (DG) of a nestin-cre mouse. (B) Cre expressed in nestin-positive
neural progenitor cells reverses mCherry and allows expression in new
neurons as they differentiate in granule neurons. mCherry expression is
therefore restricted to granule neurons born after virus injection.
For example, miR-9 is expressed in all cells in the brain with
the exception of microglia. By incorporating miR-9 binding sites
into the transgene construct, miR-9 will bind to, and degrade
transgene RNAs in all cells except microglia, resulting in selective
expression of the transgene in microglia (Akerblom et al.,
2013). Similarly, preventing transgene expression in neurons, and
enhancing astrocyte expression can be aided by incorporation
of the miR-124 binding sequences into the vector (Colin et al.,
2009). As further advances in understanding miR biology and cell
type speciﬁcity emerge, these constructs can be further reﬁned for
selective gene expression.
Temporal Control of Gene Expression
Temporal control of gene expression is achieved using inducible
promoters. These promoters are activated by an additional factor
that is added to or removed from the system. They are widely used
in bacterial expression systems and include promoters controlled
by drugs, metal ions, heat shock, or hormones – only some of
which are useable in mammalian cells, and even fewer in the
CNS where drugs need to cross the blood brain barrier. Most
commonly, drug-inducible promoters are used in neuroscience,
where the transgene is expressed under the control of a minimal
promoter sequence that is only active if bound by a transac-
tivator. The ability of this transactivator to bind the promoter
is regulated by co-factors. The most famous and widely used
inducible promoter system is the Tet-On/Oﬀ system and deriva-
tives thereof. In this system, the transgene is downstream of a
minimal promoter under the control of a Tet response element
(TRE) based on an Escherichia coli operon conferring resistance
to the antibiotic tetracycline. For use in mammalian cells, the
Tet repressor (Tet-On) is fused to the activating domain of
virion protein 16 of herpes simplex virus (VP16) that consti-
tutes the tetracycline-controlled transactivator (tTA). When tTA
binds to the TRE, transcription from the minimal promoter is
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stimulated by tetracycline or its derivative doxycycline (DOX) in
a concentration-dependent manner, thus providing a reversible
on and oﬀ switch (Gossen and Bujard, 1995; Gossen et al., 1995;
Pluta et al., 2005). In the Tet-Oﬀ system, the tTA binds to the TRE
in the absence of tetracycline and activates gene expression; when
tetracycline or DOX is administered, gene expression is repressed
(Gossen and Bujard, 1992). The Tet-On system was derived by
mutation of the tTA leading to the opposite phenotype, where
administration of tetracycline induces gene expression (Gossen
et al., 1995).
Light-inducible promoters have recently expanded the
potential of inducible promoters (Wang et al., 2012). In a system
similar to the Tet concept, a photoactivatable transactivator
dimerises upon exposure to light of a certain wavelength,
permitting it to bind to its response element and thereby induce
gene expression. The advantages of this optogenetic system over
drug-inducible promoters are the higher spatial and temporal
accuracy of induction and reversibility (ms to s resolution),
whereas tetracycline (and DOX) is usually delivered system-
ically and its eﬀects can last from hours to days (Agwuh and
MacGowan, 2006).
Some speciﬁc research questions require tight spatial and
temporal control of gene expression and aim to express the
transgene in only a speciﬁc subset of very similar cells, which
can be optimally addressed by combining several techniques.
Studying neurogenesis in the adult mammalian brain requires
several techniques to be combined to obtain the necessary
speciﬁcity. In order to only target newborn granule cells, which
are very similar to their developmentally born neighboring
granule cells, a cre transgenic mouse can be combined with
cell-type speciﬁc promoter (Figure 2). The transgenic mouse
expresses cre recombinase under a nestin promoter only present
in neural progenitor cells, which reside in the subgranular and
subventricular zones in the hippocampus. To only target newly
born cells in the hippocampus, a VSVg-pseudotyped lentivirus
with the transgene is injected into the dentate gyrus; in Figure 2,
the transgene encodes the ﬂuorescent protein mCherry. The
transgene is inverted and ﬂanked by two sets of loxP sites to
prevent leaky expression in cells without cre recombinase. By
placing the transgene under a syn promoter, it will only be
expressed in mature neurons born after the injection of the
lentivirus. Including a Tet system to induce cre expression only
at very speciﬁc time points could further enhance temporal
resolution (Chen et al., 2009).
Posttranslational Control of Gene
Expression
Posttranslational regulation of transgene expression can be used
to control neural activity by using reversibly activatable ion
channels or G-protein coupled receptors (GPCR; reviewed in
Rogan and Roth, 2011). The expressed channels and GPCRs
are responsive to either light or drugs. Below we focus on the
utility of light (optogenetic stimulation) to alter cell function or
structure because it has the most accurate (shortest) time resolu-
tion (ms) and can mimic the time course of real neural activity.
However, sophisticated, highly speciﬁc and activatable changes in
gene expression can occur over longer time frames using drugs
(min-days), so are ideally suited for examining biological states
such as circadian rhythm, sleep-wake cycle, stress, and the control
of feeding. One of the most recent advances is to completely
isolate the introduced transgene from the endogenous ligand–
GPCR combinations by developing designer receptors exclusively
activated by designer drugs (DREADDs; Armbruster et al., 2007).
One advantage of DREADDs is that both receptors and ligands
are speciﬁcally designed to have high aﬃnity to each other, but
not with other targets in vivo.
Light Inducible Control of Neuronal Function –
Optogenetics
In the ﬁeld of neuroscience, a major new application of lentivi-
ral vectors has been the development of optogenetic technology.
Optogenetic stimulation (optogenetics) is the result of 30 years
of intense research in both gene therapy and light-activated
proteins. Since the ﬁrst article in 2005 describing the use of
optogenetics in neuroscience (Boyden et al., 2005), optoge-
netics has genuinely revolutionized neuroscience research and
the number of publications using optogenetics has increased
exponentially (Aston-Jones and Deisseroth, 2013). Optogenetics
was chosen as the method of the year by the prestigious Nature
Methods journal in 2010.
The principle of optogenetics is to express a light-activated
protein in brain cells via a viral vector, such as a lentivirus,
and then activate this particular population of brain cells with
light of a speciﬁc wavelength (Figure 3A). The power of optoge-
netics resides in its spatial, temporal, and neuronal phenotype
speciﬁcity to control brain cells (Fenno et al., 2011), which was
previously lacking despite many attempts to solve it using other
neuroscience methods. Precise timing of optogenetic stimulation
is achieved by light pulses [using a laser or light emitting diode
(LED) as a light source and to deliver the light at a target area
of the brain using an optical ﬁber], at millisecond resolution,
which is in accordance with rapid generation and transmission
of action potentials at the initial segment or along the axon.
Spatial speciﬁcity is achieved by locally injecting the viral vector
into a speciﬁc part of the brain and restricting its spread to
only the target nucleus by optimizing the number of injections
and volume injected at each site to match the three dimensional
shape of the target. In cases when a target site has a neuronal
phenotype that diﬀers from surrounding nuclei, spatial speciﬁcity
is also achieved by using a promoter for that neuronal phenotype.
Spatial speciﬁcity can be further enhanced by careful position-
ing of the ﬁber optic probe for controlled application of light
within the target nucleus. Transduction of a speciﬁc population of
neurons is achieved by pseudotyping viral vectors and promoters
as described in Section “Spatial Restriction of Gene Expression”
and “Cell-Speciﬁc Gene Expression Using Promoters,” respec-
tively. Temporal control of channel activity is dependent on
activation of the laser. At ﬁrst, optogenetics was used to replace
electrical stimulation because it achieves the goal of activating
speciﬁc neuronal circuits to understand how they work with
signiﬁcantly improved accuracy. In contrast, electrical stimula-
tion has the major drawback of activating all excitable tissues in
the area, including passing ﬁbers (Bosch et al., 2011). Since 2005,
the tools for optogenetics (types and properties of light-activated
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FIGURE 3 | Blue light stimulation of neurons expressing a
channelrhodopsin alters cell activity and behavior. (A) A lentiviral vector
(LV-CaMKII-ChR2-mCherry) was injected into the motor thalamus of rats to
transduce glutamatergic neurons. Blue light stimulation of motor thalamus
opened channelrhodopsin2 cation channels in the membrane of transduced
neurons. (B) Effect of blue light stimulation of motor thalamus on movement
performance in an acute model of parkinsonism. For each pattern, the
number of reaches executed by rats is represented for 5 min before, during
and after blue light (473 nm) stimulation. Theta burst stimulation (TBS) and the
physiological reaching pattern (pReP) are irregular patterns and significantly
increased reaching performance. Conversely, the equivalent tonic patterns (15
and 6.2 Hz, respectively) did not improve reaching. ∗p < 0.05, versus
prestimulation (Tukey’s test). #p < 0.05 versus pREP pattern (Tukey’s test).
Reproduced with permission from Seeger-Armbruster et al. (2015). (C) A
similar experiment performed with injection of LV-EF1α-hChR2(H134R)-eYFP
into ventrolateral motor thalamus of a rhesus monkey. Upper panel, data
show the firing rate (spikes/bin) of one neuron before (−20–0 ms), during
(0–1.2 ms), and after (1.2–40 ms) blue light stimulation (1.2 ms pulse). The cell
responded with a brief increase of spiking activity just after the pulse of blue
light. Bottom panel, the duration of blue light stimulation affected the
responses of motor thalamus neurons; longer pulses caused larger increases
in firing rate. Reproduced with permission from Galvan et al. (2012).
proteins, promoters, viral vectors, light sources, stimulation,
and recording devices) have been rapidly developing enabling
scientists to create new paradigms and innovative approaches to
address complex scientiﬁc questions. In particular, optogenetics
can be used to dissect the anatomy and function of neuronal
circuits (Atasoy et al., 2012) and induce or restore behaviors
(Fanselow and Connors, 2005; Chaudhury et al., 2013; Seeger-
Armbruster et al., 2015; Figures 3B,C). Moreover, while electrical
stimulation has been focused on controlling neuronal activity,
optogenetics also allows manipulation of glial cells (astrocytes,
microglia), which constitutes an incomparable way to understand
the role of glia in the brain (Figueiredo et al., 2011; Li et al.,
2013).
More recently, optogenetics has evolved beyond controlling
cell excitability (ion channels). Light-activated proteins are able to
activate downstream signaling pathways, for example OptoXR, a
category of light-activated proteins that are able to activate signal-
ing pathways from Gq, Gs, or Gi proteins when they are activated
by 500 nm-light (Fenno et al., 2011). A photoactivatable version
of adenylyl cyclase is also available, which has notably been used
to increase levels of glucocorticoids to study stress responses in
zebraﬁsh (De Marco et al., 2013). Optogenetics can also work by
dimerization or interactions of the light-activated proteins upon
light stimulation, which can control an almost inﬁnite variety of
signaling pathways and have been used notably to trigger cell
migration (Pathak et al., 2013).
Lentiviruses were chosen as the viral vector for the ﬁrst article
describing optogenetics (Boyden et al., 2005). Currently, most
studies use either lentiviruses or AAVs as the vector of choice
in rodents or monkeys. Despite diﬀerences in their transduction,
speciﬁcity, and spread in the brain (Figure 1), the selection of
one or other vector is rarely explained in research articles. The
main diﬀerence between lentivirus and AAV is their ability to
diﬀuse in the brain (Packer et al., 2013). Indeed, AAV transduces a
much larger area around the injection site compared to lentivirus,
which is usually restricted to the site of injection (Figure 1).
As a consequence, AAVs are preferred when high expression
levels of light-activated proteins are needed in a large area of
the brain. AAV also seems to cause higher expression at the
cell level by inserting a larger number of copies into each cell
(Diester et al., 2011); however, this may not be advantageous.
Recent studies suggest that high level of gene transfer with
AAV increases the probability of developing aggregates of non-
native expressed proteins in cells (Diester et al., 2011) and/or
axonal malformation (Miyashita et al., 2013). This is less likely
to occur with lentivirus, due to the lower level of transduction.
Moreover, high levels of light-activated proteins lead to higher
stimulation rates, which can lead to artiﬁcial eﬀects and thus
bias the conclusions (Hausser, 2014). In contrast, lentiviruses are
preferred when spatial speciﬁcity is needed, despite lower levels
of expression, and when the genetic code for expression of the
required protein is large. In mice where transgenic technolo-
gies are well established, optogenetics is commonly performed
with transgenic mice in combination with AAV, using the cre-
lox system. In this conﬁguration, spatial speciﬁcity is achieved
by the injection of a ﬂoxed transgene construct and high level
of expression is achieved by using AAV. Overall, the choice of
viral vector is complex and depends on the experimental design
required to answer the research question and it is particularly
important because many optogenetic studies are performed on
freely moving animals, addressing complex behavioral questions
over weeks or months.
In the few studies performing optogenetics in monkey,
lentivirus and AAV have both been used successfully (Han et al.,
2009; Diester et al., 2011; Galvan et al., 2012; Lerchner et al., 2014)
with the diﬀerence that lentivirus leads to a smaller proportion of
aggregates and may thus be a better option for long term studies,
as is usually the case with monkeys.
In the future, optogenetics may evolve towards more speciﬁc
stimulation of neuronal populations with fewer side eﬀects, and
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lentiviral tools may play a key role in this. For basic neuroscience
research, one of the ultimate goals of optogenetic stimula-
tion techniques is to mimic activity in a normally functioning
neuronal network to understand the neuronal coding responsi-
ble for brain function (Seeger-Armbruster et al., 2015). Another
perspective is to use optogenetics with very speciﬁc patterns of
light stimulation (such as theta burst stimulation in the cortex)
to promote plasticity and restore normal behavior in a brain
with a neurological disorder (Seeger-Armbruster et al., 2015).
A potential future extension of optogenetics will be its use in
humans. Although lentivirus has a limited transduction capacity
compared to AAV, this is less important when combined with
optogenetic stimulation because that the area of brain transduced
by the vector and stimulated by the ﬁber-optic probe are of
similar size. From this perspective, lentivirus may be preferred
for optogenetic stimulation to treat or cure neurological diseases
in humans in the future because of its speciﬁcity and limited
long-term toxicity on brain tissue.
Exploring Neuronal Circuitry in the Brain
Another ﬁeld being redeﬁned by lentiviral vectors is neural
tracing. Lentivirus provides several advantages with spatially
deﬁned expression and combinations of tracers with optoge-
netic and other functional constructs allowing examination
of questions not previously possible using traditional tracing
techniques.
Analysis of neuronal circuitry has traditionally relied on
neuronal tracers such as biotinylated dextran amine (BDA),
phaseolus vulgaris leucoagglutinin (PHAL), wheat-germ
agglutinin (WGA), horseradish peroxidase (HRP), cholera toxin,
and more recently pseudorabies virus to label neuronal pathways
(Callaway, 2008; Huh et al., 2010). Some of these tracers label
neurons in a predominantly anterograde [high molecular weight
(Mr) BDA, PHAL] or retrograde (low Mr BDA, pseudorabies,
cholera toxin, HRP), or bidirectional (WGA) way. While these
tracers confer spatial speciﬁcity that is dependent on the volume
injected, all neurons in the injected region are labeled regardless
of the phenotype.
More recently, lentiviral vectors have been combined with
microscopy and other biological techniques to investigate the
anatomy of neural circuits in many brain areas, including
the cerebral cortex, thalamus, basal ganglia, hippocampus, and
brainstem (Trono, 2000; Vigna and Naldini, 2000; Duale et al.,
2005; Grinevich et al., 2005; Benzekhroufa et al., 2009; Huh et al.,
2010; Takada et al., 2013; Figure 4). Depending on the lentivirus
type and the promoter used in the construct, viral vectors can
transduce dendrites, the somata, and terminals of neurons and
express proteins at a particular subcellular component, such as in
the cell membrane or nucleus (Klein et al., 1998; Gradinaru et al.,
2010; Lobbestael et al., 2010; Konermann et al., 2013; Dautan
et al., 2014). With careful experimental design, viral vectors
can accurately label a particular neuronal phenotype, which
aﬀords the possibility of labeling just one distinct pathway in the
brain (Tye and Deisseroth, 2012; Dautan et al., 2014; Hasegawa
et al., 2014). In addition to spatial speciﬁcity, viral vectors allow
temporal speciﬁcity in neuroanatomy studies, determined by the
time of injection and harvesting of tissue (Dull et al., 1998;
FIGURE 4 | Visualization of lentivirus transduced neurons in
post-mortem tissue and in situ imaging. (A) Injection of
B19/VSVg-LV-GFP into the lumbar spinal cord resulted in prominent
transduction of neurons in the brainstem. Scale bar = 50 μm. Reproduced
with permission from Schoderboeck et al. (2015). (B) An electron micrograph
of a lentivirus transduced spine in the monkey striatum expressing eYFP.
eYFP-tagged neuronal elements were made electron dense by using
immunoperoxidase labeling with DAB as the chromogen, prior to general
processing for electron microscopy. Reproduced with permission from Galvan
et al. (2012). (C) In situ BOLD signals from opto-functional MRI in mice (Desai
et al., 2011). Channelrhodopsin-GFP expression following injection of
LV-FCK-ChR2- GFP into the somatosensory cortex (left). Voxels with
significant increases in BOLD signal (color scale) are shown 1 mm posterior to
bregma (right). Reproduced with permission from Desai et al. (2011).
Takada et al., 2013). In contrast, immunohistochemistry labels
all neurons of a phenotype irrespective of the pathways that they
belong to and only selected brain slices are stained and analyzed,
which means that neurons of interest are only partially visualized
(e.g., axon and terminals, but not somata and dendrites, or the
converse), unless large numbers of serial sections are analyzed.
Viral vectors permit neurons to be transduced in a controlled
area of the brain (Huh et al., 2010) because they diﬀuse smaller
distances than traditional neuronal tracers, however, transduc-
tion of large populations of neurons can be achieved by injecting
a larger volume, injecting multiple times or using a higher titre
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(Miyoshi et al., 1997; Cai et al., 2013). Furthermore, it is possible
to combine viral vectors with conditional systems so that neurons
are labeled during a speciﬁc period of development (Dull et al.,
1998; Wiznerowicz and Trono, 2003). Helper-viruses have also
been used in short-term anatomical experiments to speciﬁcally
label excitatory and inhibitory pathways to better understand
whole circuits and to improve cloning capacity (Kumar-Singh,
2008; Liu et al., 2013). For all of these reasons, viral vectors permit
unprecedented precise descriptions of pathways and connections
for subpopulations of neurons.
As described in Section “Spatial Restriction of Gene
Expression,” lentiviral vectors can be pseudotyped with envelopes
that modify vector uptake, allowing neuronal tracing studies
to be conducted. VSVg-pseudotyped vectors transduce neurons
and astrocytes only within the local injection site. Delivery
of a cytoplasmic-localized transgene via a VSVg-lentivirus will
result in labeling of cell soma within the injection site and ﬁlls
their projections, allowing tracing of neural target zones. In
contrast, Rbg-pseudotyped lentiviral vectors deliver transgenes
both locally and via retrograde transport to distal somata with
axonal projections localized in the injection zone (Mazarakis
et al., 2001; Figure 1). The transgene-encoded protein is
expressed by transduced neurons – the precise site of expression
(e.g., axon, nucleus, cell membrane, histone residues of DNA,
etc.) is dependent on where the targeted protein is usually located
in the cell. This labeling speciﬁcity can be critical because of the
complexity of the brain. Here, lentiviral vectors oﬀer improved
speciﬁcity because most AAV serotypes would label both aﬀerent
and eﬀerent neurons in the region (Klaw et al., 2013; Figure 1).
In addition, the ﬂexibility to have the vectors endocytosed at the
terminals or somata of target neurons means that the investi-
gator can select the vector so that injection and uptake is in
an area that will not be visualized (Schoderboeck et al., 2015;
Figure 4A). The advantage for experiments with an anatomi-
cal focus is that the physical damage or artifact caused by the
injection does not interfere with the interpretation or analysis
of images taken at high-resolution, such as electron microscopy.
For example, if the somata of neurons will be visualized, injection
damage will be minimized by targeting uptake at the terminals
of the neurons of interest by using a vector containing a Rbg
envelope. Conversely, if the terminals will be visualized, the
injection should be targeted at the somata of the neurons of
interest by using a VSVg envelope.
Neuroanatomy studies using lentiviral vectors can also be
enhanced by combining with other techniques. Generally, the
reporter ﬂuorophores expressed by transduced neurons are
imaged post-mortem using ﬂuorescence or confocal microscopy,
and often immunohistochemical staining is conducted to conﬁrm
that a subpopulation of neurons has been transduced. However,
these techniques can be further exploited to determine which
cellular compartments express the proteins (Pastrana, 2011;
Konermann et al., 2013), for example using epitope tags
(Lobbestael et al., 2010), or to detect structural elements, such
as synapses, that cannot be deﬁnitively determined using light
microscopy (Shu et al., 2011; Galvan et al., 2012). Improved tissue
clearing techniques (Hama et al., 2011; Chung et al., 2013; Ke
et al., 2013) and microscope optics have enabled visualization
of transduced neurons in whole brains, and although this has
been done using AAVs so far (Deisseroth and Schnitzer, 2013;
Tomer et al., 2014; Yang et al., 2014), lentiviral vectors could be
used to provide greater spatial speciﬁcity. Electron microscopy
is another option that permits visualization of small structural
elements and subcellular compartments to investigate circuitry
at the ultrastructural level. This can be achieved by immuno-
histochemically tagging the ﬂuorophore expressed by the viral
vector and labeling it with an electron dense chromogen such as
intensiﬁed diaminobenzidine (DAB, Figure 4B), using a genetic
tag (miniSOG) that polymerizes DAB when exposed to blue light,
or application of immunogold particles during postmortem tissue
processing (Grinevich et al., 2005; Sosinsky et al., 2007; Scotto-
Lomassese et al., 2011; Shu et al., 2011; Galvan et al., 2012;
Dautan et al., 2014; Pollock et al., 2014). By combining lentivi-
ral vectors, optogenetic stimulation, and cutting edge process-
ing techniques for electron microscopy, such as high pressure
freezing, the impact of changes in physiology on anatomical
circuits can be investigated (Watanabe et al., 2014). Furthermore,
because lentiviral vectors produce little to no immune or inﬂam-
matory response compared to many other vectors (Blomer et al.,
1997), they maintain normal morphology and cellular composi-
tion in the area to be investigated, which is critical for studies at
the ultrastructural level. This technology could be extended to
examine the consequence of activating a G-protein by optoge-
netic stimulation and imaging how that changes the location
of proteins in neurons, thus providing a greater understanding
of the function and interactions of proteins at the subcellu-
lar level (Pastrana, 2011; Konermann et al., 2013). Thus, viral
vectors and lentiviruses in particular, have broad utility to investi-
gate neural circuits at synapse, neuronal, and complete circuit
levels.
Importantly, the anatomy of brain circuitry can also be
explored in vivo by imaging neurons transduced by a viral vector
in situ using functional magnetic resonance imaging (fMRI) or
bioluminescence. Bioluminescence imaging in vivo requires a
reporter gene to encode a bioluminescent enzyme that generates
light, usually in yellow-infrared spectral wavelengths, which are
detected by the biosensor without using invasive procedures
(Massoud et al., 2008; Shah et al., 2008). Generally, imaging of
structures deep within an animal or tissue block is facilitated
by having a longer wavelength (Contag and Bachmann, 2002;
Zhang et al., 2007). Bioluminescence imaging is limited by its
low resolution because light is scattered in body tissues; however,
this imaging does provide valuable structural information within
an animal (Contag and Bachmann, 2002). Bioluminescence
imaging has been used to investigate therapeutic applications
of gene expression using AAV, (Contag and Bachmann, 2002),
adenovirus (Cho et al., 2005; Massoud et al., 2008), and
lentiviral vectors (Deroose et al., 2006). Combining optogenetic
stimulation of transduced neurons with fMRI oﬀers a greater
understanding of how neural activity alters blood oxygen level
dependent (BOLD) signals at stimulated and downstream sites
(Adriani et al., 2010; Lee et al., 2010; Desai et al., 2011; Figure 4C).
In addition, positron emission tomography (PET) has been
used to image changes in brain glucose metabolism following
optogenetic stimulation to examine functionally connected brain
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structures (Thanos et al., 2013). Neurons transduced with lentivi-
ral vectors express non-native proteins for at least 6 months
(Blomer et al., 1997), enabling changes in structure to be assessed
over long periods of time, thus may provide insights to disease
processes, for example, changes in structure associated with
animal models of neurodegenerative diseases such as Alzheimer’s.
An alternative method to trace transduced neurons in more
superﬁcial areas of the brain in situ is to create a window for
imaging transduced neurons via multiphoton microscopy. This
usually involves live cell imaging to explore when and how large
populations of neurons interact as a network (Shah et al., 2008;
Mittmann et al., 2011; Knöpfel, 2012), but could be extended to
investigate anatomical studies over time.
In the future, there are many ways that lentiviral vectors
could be combined with imaging techniques and explor-
ing these possibilities will greatly improve knowledge of the
anatomy of neural circuits. Some applications may include
optogenetic stimulation and clearing post-mortem tissue to
examine a circuit within large blocks of brain for imaging
using confocal microscope. Alternatively optogenetic stimula-
tion combined with high pressure freezing of the tissue and
electron microscopy would permit activity-dependent changes
in ultrastructural circuitry to be investigated. Enhancing the
resolution of in situ imaging by fMRI or bioluminescence would
greatly improve knowledge of how circuitry changes over time
in animal models of neurodegenerative diseases. Future improve-
ments might include development of brain bow-like technology
(Weber, 2012) using lentiviral vectors so that multiple pathways
and neuronal phenotypes can be investigated in whole brains.
The exciting prospect is to explore new combinations of lentivi-
ral gene therapy with optogenetic stimulation, tissue processing,
and imaging to address previously unprecedented neuroscience
questions about health and disease.
Current Limitations and Future
Prospects
Our understanding of the brain is rapidly expanding.
Sophisticated technologies allow us to answer complex questions,
understand gene function, and visualize the anatomy of neural
circuits. The use of viral vectors is enhancing much of this
work. Viral vectors have developed substantially from basic gene
addition or knockdown with constitutive promoters to drug and
light regulation of gene and protein expression. Further reﬁne-
ments of vectors, promoter regulation and transgenes continue.
One recent example illustrating the potential of vectors in
neuroscience involves mind-controlled gene regulation (Folcher
et al., 2014). Combining EEG recorded brain waves and a
computer interface, gene expression and/or optogenetic channel
activity can be remotely regulated and changes in behavior can be
measured. While this is currently in the proof-of concept phase,
such technology has huge implications for the treatment of many
brain disorders including epilepsy and Parkinson’s disease.
Clinically, lentiviral vectors have predominantly been used to
transduce cells ex vivo, which have then been later transplanted as
a reservoir for production of useful gene products. To date AAV
and lentivirus have been used to treat Parkinson’s disease using
standard gene therapy technology and although AAV has been
preferred for injection into humans because it does not cause any
known pathology, both AAV and lentivirus appear to be safe and
well-tolerated by these patients (LeWitt et al., 2011; Palﬁ et al.,
2014). The translatability of lentivirus use is currently limited by
its restricted spread in large brains; however, further modiﬁcation
of envelope glycoproteins or injection strategies will alleviate this
clinical dilemma in the future.
The frontiers of modern biological science will be expanded by
developing new biological tools and reﬁning new technologies by
collaborative research teams with skills ranging from molecular
biology and viral development to functional neuroanatomy and
physiology. Involvement by clinical teams will ensure that these
technologies address health-related questions and are readily
translated to the clinical setting to improve the health and wellbe-
ing of patients.
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